The FDA’s Center for Biologics Evaluation and Research (CBER) will host a virtual scientific public workshop on September 23, 2026, titled “Next-Generation Sequencing (NGS) for Adventitious Agent (AA) Detection in Biologics.” The event will bring together subject matter experts and stakeholders to discuss the readiness of NGS technologies for AA detection, examine current challenges, and explore potential approaches to support broader adoption of NGS-based methodologies in biological product testing.
NGS-based AA detection methods are emerging as new approach methodologies (NAMs) that can help enhance the safety of biological products while reducing reliance on animal testing. Workshop discussions will focus on the use of NGS technologies to detect a broad range of adventitious agents, including:
The event will also address challenges associated with detecting adventitious viruses, particularly given the genetic diversity of viral populations and the ongoing emergence of new viral variants. These topics are relevant to a range of CBER-regulated biological products, including cell and gene therapies, xenotransplantation products, blood products, and vaccines.
Workshop Objectives:
Visit the event page for more information.